Pfizer (NYSE: PFE) will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (NYSE: HLN), lowering its stake in […]
Pfizer to Sell $3 Billion Stake in Sensodyne Maker Haleon Read More »
Pfizer’s (NYSE: PFE) experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of
Pfizer’s Bladder Cancer Therapy Meets Main Goal in Late-Stage Study Read More »
NEW YORK – Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer (NYSE: PFE) COVID-19
Drugmakers to Hike US Prices on Over 250 Medications Starting January 1 Read More »
NEW YORK – Executives from Pfizer (NYSE: PFE) and Amazon.com (NASDAQ: AMZN) see opportunities for working with U.S. Health Secretary
Amazon, Pfizer Execs Seek Common Ground with RFK Jr on Climate Risks to Health Read More »
President-elect Donald Trump met with the chief executives of U.S. drugmakers Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) as
Trump, RFK Jr. Met with Pfizer, Lilly Executives: Report Read More »
LONDON – On Tuesday, Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) won their attempt to invalidate two
Pfizer and BioNTech Win Bid to Invalidate CureVac’s UK COVID Vaccine Patents Read More »
U.S. sales of RSV vaccines from GSK (NYSE: GSK) and Pfizer (NYSE: PFE) are down significantly after regulators narrowed the
Pfizer and GSK RSV Vaccine Sales Fall in US as Millions Fewer People Line Up Read More »
LONDON – On Monday, Pfizer (NYSE: PFE) won a bid in a London court to invalidate two of GSK’s (NYSE:
Pfizer Secures Legal Victory Against GSK in RSV Vaccine Patent Dispute Read More »
Pfizer (NYSE: PFE) sold a stake in British consumer healthcare group Haleon (NYSE: HLN) worth about $3.26 billion on Monday,
Pfizer (NYSE: PFE) Cuts Haleon Stake to 15%, Selling $3.3 Billion in Shares Read More »
On Thursday, the European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer’s (NYSE: PFE) sickle cell disease drug
EU Regulator Recommends Suspension of Pfizer’s Sickle Cell Disease Treatment Read More »
Pfizer’s (NYSE: PFE) decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death
Analysts Say Pfizer’s Oxbryta Exit Could Speed Up Trials for Rival Sickle Cell Drugs Read More »
LONDON – Pfizer (NYSE: PFE) and Moderna’s (NASDAQ: MRNA) legal battle over their rival COVID-19 vaccines will continue after London’s
Pfizer vs. Moderna: COVID Vaccine Patents Battle to Go to Appeal in UK Read More »
On Thursday, the U.S. Food and Drug Administration approved updated COVID-19 vaccines made by Pfizer (NYSE: PFE) and Moderna (NASDAQ:
FDA Greenlights Updated COVID Vaccines to Combat New Variants Ahead of Fall Campaign Read More »
On Monday, Pfizer (NYSE: PFE) said its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a
Pfizer’s (NYSE: PFE) RSV Vaccine Proves Effective for Immuno-Compromised Adults in Study Read More »
Pfizer (NYSE: PFE) raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal
Pfizer (NYSE: PFE) Lifts Annual Profit Outlook with Surge in Cancer and Heart Drug Sales Read More »
Pfizer (NYSE: PFE) stock saw a marginal increase in intraday trading Monday following the appointment of a new Chief Strategy
Pfizer (NYSE: PFE) Stock Edges Up After Naming New Chief Strategy Officer Read More »
Pfizer (NYSE: PFE) stock inclined about 2% in intraday trading Thursday after BMO raised its price target. BMO Capital Markets
Pfizer (NYSE: PFE) Stock Gets Boost as BMO Raises Price Target Read More »
Pfizer (NYSE: PFE) stock jumped 6% in intraday trading Wednesday following the release of its first-quarter earnings report. Investors reacted
Pfizer (NYSE: PFE) stock rebounded from their 11-year low on Wednesday following bullish remarks from the CEO of Ritholtz Wealth
Pfizer (NYSE: PFE) Stock Surges on Upbeat Commentary from Ritholtz Wealth Management CEO Read More »
Pfizer (NYSE: PFE) stock declined almost 2% on Tuesday after its ReutersQ4 earnings report revealed a mix of results, with
Pfizer (NYSE: PFE) Stock Drops on Mixed Q4 Earnings Read More »
Pfizer (NYSE: PFE) stock fell more than 2% on Thursday, even though Canadian regulators approved its Gene Therapy for Hemophilia
Shares of Pfizer Inc. (NYSE: PFE) and German partner BioNTech (NASDAQ: BNTX) fell in pre-market trading after the leading U.S.
In a recent disclosure with the Securities & Exchange Commission, it has been revealed that Churchill Management Corp, a notable
Churchill Management Corp Cuts Stake in Pfizer (PFE) by 90.6% in Q1: SEC Filing Read More »
Pfizer Inc. (NYSE: PFE) announced today that it is discontinuing the development of its once-a-day experimental obesity pill due to
Pfizer (PFE) Shares Plummet Over 5% Today, But Why? Read More »
Copyright © 2025 abbonews.com
